Clinical Trials: Page 143
-
AZ's new formulation performs well in phase III diabetes study
In a 28-week study, exanatide once-weekly suspension for autoinjection was as effective as twice-daily exanatide injection for glycemic control.
By Nicole Gray • Sept. 22, 2014 -
Lilly enters crowded diabetes field as FDA approves once-weekly Trulicity
Can the clinically impressive once-weekly treatment compete with Novo's Victoza?
By Sy Mukherjee • Sept. 19, 2014 -
Explore the Trendline➔
Getty Images
TrendlineOncology's research boom
More than one quarter of the medcines cleared by the FDA's main review office since 2015 have been cancer drugs, a tally that reflects the advent of cancer immunotherapy as well as continued progress in matching treatment to genetics.
By BioPharma Dive staff -
Gilead's pancreatic cancer hopeful crashes in phase II
Progression-free survival didn't budge even when researchers combined simtuzumab with standard of care in high doses.
By Nicole Gray • Sept. 18, 2014 -
Avanir Pharma soars to 8-year high on positive Alzheimer's drug results
AVP-923 could become a first-in-class treatment for agitation in Alzheimer’s disease patients.
By Nicole Gray • Sept. 16, 2014 -
Roche starts phase III trials for advanced wet AMD drug
If approved, lampalizumab will become the first treatment for advanced wet macular degeneration---also known as geographic atrophy.
By Nicole Gray • Sept. 16, 2014 -
Roche's cheaper vision loss drug just as effective as Novartis' Lucentis
Novartis’ Lucentis and Roche’s Avastin are similarly effective against wet age-related macular degeneration. But only one is approved for treating the condition -- even though the other is far cheaper.
By Nicole Gray • Sept. 16, 2014 -
Asterias, Cancer Research UK to collaborate on lung cancer vaccine
The companies will be hoping for better results than Merck KGaA, which was forced to shut down its own lung cancer vaccine trial last week.
By Nicole Gray • Sept. 15, 2014 -
Dompé bullish on novel eye disease treatment
Italy-based Dompé has successfully completed clinical studies on a novel new treatment for the incurable neurotrophic keratitis.
By Nicole Gray • Sept. 15, 2014 -
FDA approves controversial weight loss pill Contrave
The second time's the charm for Orexigen and Takeda's highly-anticipated weight loss drug.
By Sy Mukherjee • Sept. 11, 2014 -
FDA approves expanded use of Xtandi for prostate cancer
Xtandi-treated men with chemotherapy-naïve prostate cancer were able to defer chemo for 17 months in a trial.
By Nicole Gray • Sept. 11, 2014 -
NICE demands more transparency from pharma
The agency threatens to bypass companies and go straight to regulators if pharma firms fail to provide sufficient data for review.
By Nicole Gray • Sept. 11, 2014 -
Severe misconduct: Hyperion and Evotec halt diabetes drug trial
Employees were found to have manipulated trial data to show more favorable findings.
By Nicole Gray • Sept. 11, 2014 -
Deep Dive
New statin guidelines: Thoughts from a physician on the front lines
“It seems that just about everyone over the age of 65 needs to be on a statin based on the new guidelines,” says Dr. Barry Mennen.
By Nicole Gray • Sept. 11, 2014 -
A good deal for Roche just got better: Intermune reports new Esbriet data
Based on newly-available 72-week data, Esbriet (pirfenidone) significantly reduces the risk of mortality in idiopathic pulmonary fibrosis patients.
By Nicole Gray • Sept. 10, 2014 -
Astrazeneca not deterred when COPD drug fails to meet primary endpoints
Benralizumab is the first biologic to show marked reduction of eosinophils.
By Nicole Gray • Sept. 10, 2014 -
FDA narrowly rejects Actavis' blood pressure combo
The agency isn't convinced the dual-treatment is more effective than monotherapy.
By Sy Mukherjee • Sept. 10, 2014 -
NICE rejects Celgene's Abraxane for pancreatic cancer
Abraxane (nab-paclitaxel) has failed the "value-for-money" test.
By Nicole Gray • Sept. 9, 2014 -
GSK, Gilead's pulmonary hypertension combo smashes goals in phase III trial
Combination therapy using ambrisentan and tadalafil significantly reduced pulmonary hypertension patients' risk of death and hospitalization.
By Sy Mukherjee • Sept. 8, 2014 -
Game on: Novartis' COPD drug bests GSK blockbuster in phase III trials
Novartis' Ultibro could be real competition for GSK's blockbuster COPD treatment, Seretide.
By Nicole Gray • Sept. 8, 2014 -
Feds ink $25 million contract with Ebola drug maker Mapp Biopharma
The 18-month contract for the production of ZMapp can be extended to upwards of $42 million.
By Sy Mukherjee • Sept. 3, 2014 -
AstraZeneca's Brilinta falls short in phase IV study
But the trial still identified some upsides to using the drug.
By Nicole Gray • Sept. 3, 2014 -
Exelixis prostate cancer drug falls flat in trials, prompts massive layoffs
Exelixis will slash its workforce by 70% and refocus its efforts with cabozantanib towards treating other cancers.
By Nicole Gray • Sept. 2, 2014 -
AZ's PD-1 immunotherapy drug advances in colorectal cancer studies
MEDI-4736 is one of four PD-1 immunotherapy drugs currently being developed for cancer therapy.
By Nicole Gray • Sept. 2, 2014 -
Novartis soars on groundbreaking heart failure drug trial results
"This is going to become one of our key brands," said Novartis exec David Epstein of LCZ696.
By Nicole Gray • Sept. 2, 2014 -
Sanofi, Regeneron reveal positive data from alirocumab cholesterol trials
The game is on for Sanofi and Regeneron as they try to take on Amgen's competing PCSK9 inhibitor, evolocumab.
By Nicole Gray • Sept. 2, 2014
Previous
